| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information.
|
|
Medicine details |
|
| Medicine name | paliperidone (Byannli®) |
| Formulation | 700 mg, and1000 mg prolonged-release suspension for injection |
| Reference number | 3872 |
| Indication | Maintenance treatment of schizophrenia in adult patients who are clinically stable on 1‑monthly or 3‑monthly paliperidone palmitate injectable products (for 6-monthly administration) |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 13/07/2022 |